Chronic Total Occlusion Stenting
Baylor Hamilton Heart and Vascular Hospital is a referral center for highrisk patients with coronary artery disease seeking treatment for totally occluded arteries with chronic total occlusion ( CTO ) stenting . An option to bypass surgery or traditional stenting , interventional cardiologists thread a wire catheter against the standard flow of blood in the artery to the site of the blockage . Traditionally , total blockages of the coronary artery have been difficult to clear with interventional procedures . New technology makes fine movement of the guide wire tip much easier to control than in the past . Baylor Hamilton Heart and Vascular Hospital is among just a handful of facilities in Texas offering this service to address coronary obstructions .
In the last few years , the success rate of the combined percutaneous approach has increased from about 60 percent to more than 85 percent . This is in comparison to the success rate of about 98 percent for percutaneous treatment of non-total blockages . Although the percutaneous approach has potential complications , the complication rate is comparable to that of standard angioplasty ( about 1 percent ).
In addition to being one of the highest volume CTO cardiac centers in the nation , the hospital is also dedicated to research and innovation . Baylor Hamilton Heart and Vascular Hospital is participating in the CTO Progress Registry , a national database of elite cardiac centers nationwide that share data to identify best practices and best outcomes , and patients benefit from CTOrelated studies including various research trials to drive innovation . As one of four participating organizations in Texas , it is an honor for the hospital and participation differentiates the program ’ s capabilities from many others .
132
Total
Image courtesy of Medtronic
CTOs performed at Baylor Hamilton Heart and Vascular Hospital in Dallas
( FY17 )
Baylor Hamilton Heart and Vascular Hospital participated in this registry ( FY17 )
FIRST IN TEXAS : RESOLUTE ONYX ™ DRUG- ELUTING STENT
Baylor Hamilton Heart and Vascular Hospital became the first hospital in Texas and second in the U . S . to implant a next generation stent unlike others available . The latest advance in drug-eluting stents , the Medtronic Resolute Onyx™ Drug-Eluting Stent , was FDA approved in early May 2017 to treat coronary artery disease .
Resolute Onyx drug-eluting stent offers the widest range of sizes , expanding the treatment options available for patients . The technology of the stent ’ s structure allows for greater flexibility as the stent is placed inside a patient ’ s artery by an interventional cardiologist . The sizes offered also allow for larger size vessels , which is unique to this particular stent .
“ If you have coronary artery disease and need treatment , interventional cardiologists on the medical staff at Baylor University Medical Center at Dallas have access to advances in drug-eluting stent technology , which offers better treatment options to more patients ,” says Kevin Wheelan , MD , chief of medical staff at Baylor Hamilton Heart and Vascular Hospital . “ Keeping with the tradition of advancing cardiovascular treatment , we are proud to offer this latest generation drug-eluting stent to patients .”
“ One of the unique key features to the Onyx drug-eluting stent is the deliverability of the stent especially for larger vessels sized 4.0 or 5.0 mm . This flexibility is important in the newest generation of drug eluting stents ,” says Robert Stoler , MD , FACC , FSCAI , medical director for cardiac catheterization . “ The stent was designed for PCI using the transradial approach , giving interventional cardiologists multiple options for their patients .”
Interventional Cardiology
OUTCOMES 2017
33